[Ginkgolip, a new geriatric drug. Results of a double-blind study].
The results of a placebo controlled double blind study with Ginkgolip on 50 hospitalized patients are reported. All patients showed symptoms of cerebrovascular insufficiency. For evaluation psychometric and psychopathometric test methods were applied. Further evaluation of the patients symptoms was carried out by the investigator, by the attending staff, by the patients, using a special rating scale. The final symptoms showed significant improvements of perceptible ability, concentration, adaptability, social ability, depression and wakefulnes. The evaluation by the attending staff showed an improvement of social behaviour, time of reaction and perceptible ability. The patient's rating scale showed a lower rate of complaints of the Verumgroup than of the Placebo-group. The psychometric and psychopathometric test methods showed no showed no significant differences. The drug was well tolerated, there were no incompatibilities or side effects.
D000368:Aged; D001143:Arousal / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005971:Glutamates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D010936:Plant Extracts / Q000627:therapeutic use*; D012917:Social Adjustment; D014810:Vitamin E / Q000627:therapeutic use*
D004338:Drug Combinations; C038118:Ginkgolip; D005971:Glutamates; D010936:Plant Extracts; D014810:Vitamin E
Ginkgolip, ein neues Geriatrikum. Ergebnisse einer Doppelblindstudie.